Sunday, February 15, 2009 4:00:44 PM
--------------------------------------------------------------------------------
10-Feb-2009
Entry into a Material Definitive Agreement, Financial Statements and
Item 1.01 Entry into a Material Definitive Agreement
On February 6, 2009, Walter Industries, Inc. ("Walter"), a Delaware corporation, and its direct wholly owned subsidiaries, JWH Holding Company, LLC ("JWHHC"), a Delaware limited liability company and Walter Investment Management LLC("Spinco"), a Delaware limited liability company entered into
(i) a second amended and restated agreement and plan of merger (the "Restated Merger Agreement") with Hanover Capital Mortgage Holdings, Inc. ("HCM"), a Maryland corporation and (ii) an assignment and assumption agreement of the voting agreement dated September 29, 2008 (the "Voting Agreement Assignment") with HCM, John A. Burchett ("Burchett"), Irma N. Tavares ("Tavares"), and Amster Trading Company and Ramat Securities LTD (collectively, the "Amster Parties"). These agreements were entered into in connection with the proposed separation of Walter's financing business, including certain related insurance businesses, which currently are directly owned by JWHHC, from Walter through a series of transactions culminating in a distribution (the "Distribution") of the limited liability interests in Spinco to a third party exchange agent on behalf of Walter's stockholders, and the subsequent merger of Spinco into HCM, with HCM continuing as the surviving corporation.
Restated Merger Agreement
Walter, JWHHC, Spinco and HCM entered into the Restated Merger Agreement, which amends and restates the Amended and Restated Agreement and Plan of Merger, dated October 28, 2008, among Walter, JWHHC and HCM to, among other things,
(i) clarify that the financing business of JWHHC will be acquired by Walter and Walter will contribute the financing business to Spinco, which will merge with HCM, and (ii) extend the termination date of the agreement to June 30, 2009. The Restated Merger Agreement provides that, in connection with the merger, the surviving corporation will be renamed "Walter Investment Management Corp."
This modification will not change the relative post-merger ownership of the surviving corporation by holders of equity interests in Spinco and HCM, respectively, and therefore it will continue to be the case that, as a result of the merger, and subject to certain adjustments, immediately after the effective time of the merger holders of common stock of Walter on the record date for the spin-off (by virtue of their ownership of limited liability company interests in Spinco after the spin-off) and certain holders of options to acquire limited liability company interests in Spinco will collectively own 98.5%, and HCM stockholders will collectively own 1.5%, of the shares of common stock of the surviving corporation outstanding or reserved for issuance in settlement of restricted stock units of the surviving corporation. It will also continue to be the case that, in the merger, every 50 shares of HCM common stock outstanding immediately prior to the effective time of the merger will be combined into one share of surviving corporation common stock.
Voting Agreement Assignment
Simultaneously with the execution and delivery of the Restated Merger Agreement, Walter, JWHHC, Spinco, HCM, Burchett, Tavares and the Amster Parties, entered into the Voting Agreement Assignment, pursuant to which Walter, Burchett, Tavares and the Amster Parties consented to JWHHC's assignment of and Spinco's assumption of all of JWHHC's rights and obligations under the Voting Agreement dated September 29, 2008 (the "Voting Agreement"). Pursuant to the terms of the Voting Agreement, Burchett, Tavares and each of the Amster Parties is required to, among other things, vote their shares of HCM common stock in favor of the Restated Merger Agreement and related transactions at any meeting of HCM's stockholders.
Recent HCM News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/24/2024 10:09:13 AM
- HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda • GlobeNewswire Inc. • 09/24/2024 07:00:00 AM
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 • GlobeNewswire Inc. • 09/17/2024 03:22:47 PM
- HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer • GlobeNewswire Inc. • 09/09/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/30/2024 10:13:25 AM
- HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China • GlobeNewswire Inc. • 08/30/2024 04:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/22/2024 10:10:42 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/21/2024 10:07:52 AM
- HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia • GlobeNewswire Inc. • 08/21/2024 08:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/31/2024 11:13:18 AM
- HUTCHMED Reports 2024 Interim Results and Provides Business Updates • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status • GlobeNewswire Inc. • 07/04/2024 12:00:00 AM
- HUTCHMED to Announce 2024 Half-Year Financial Results • GlobeNewswire Inc. • 06/26/2024 08:30:00 AM
- Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 • GlobeNewswire Inc. • 06/24/2024 09:30:00 AM
- HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda • GlobeNewswire Inc. • 06/21/2024 08:00:00 PM
- HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology • GlobeNewswire Inc. • 06/17/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/07/2024 10:25:35 AM
- HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China • GlobeNewswire Inc. • 06/07/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 10:13:17 AM
- HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine • GlobeNewswire Inc. • 06/03/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/31/2024 10:12:22 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/24/2024 10:06:58 AM
- HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 05/24/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/17/2024 02:02:55 PM
- HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees • GlobeNewswire Inc. • 05/17/2024 02:00:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM